OTA, Fighting For Its Life In Congress, Draws From Both Sides Of The Aisle

vote with bipartisan backing, but the true test is yet to come. ON SHAKY GROUND: Director Rodger Herman notes that the House plan to save OTA can still be undone in the Senate. Even as the United States House of Representatives moved toward what many viewed as inevitable - a vote to abolish the 23-year-old Office of Technology Assessment (OTA) - the agency's director, Roger Herdman, headed for the office of Sen. Arlen Specter (R- Pa.). Herdman hoped the presidential aspirant would help halt th

Written bySteve Sternberg
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Even as the United States House of Representatives moved toward what many viewed as inevitable - a vote to abolish the 23-year-old Office of Technology Assessment (OTA) - the agency's director, Roger Herdman, headed for the office of Sen. Arlen Specter (R- Pa.). Herdman hoped the presidential aspirant would help halt the anti-OTA juggernaut in the Senate.

To Herdman's surprise, late last month the House narrowly approved a compromise - contained in an amendment to the House's $1.7 billion Legislative Branch Appropriations Bill - that would spare the embattled agency, trim its $22 million budget by about one-third, and move OTA into the Library of Congress.

Nevertheless, Herdman points out, that compromise still can be undone in the Senate, which later this summer must vote on its own appropriations measure detailing spending limits for Congress. After that, it must also survive conference-committee budget wrangling between the two houses.

So Herdman, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies